The Biological Activity of the Protease Enzyme Extracted from Basidiomycete Inocutis tammaricis: Antibacterial, antioxidant, and antitumor roles of naturally produced protease enzyme by Inocutis tammaricis
Main Article Content
Abstract
The basidiomycete Inocutis tamaricis is a medicinal fungus belonging to the family Hymenochaetaceae. This study evaluates the biological activities of a protease enzyme extracted from I. tamaricis, focusing on its antimicrobial, antioxidant, and antitumor potential. Antimicrobial activity was assessed using the agar well diffusion method against several pathogens at concentrations of 25, 50, and 100 μg/ml. The results demonstrated that the enzyme has exclusive inhibitory activity against gram-positive bacteria, specifically Enterococcus faecalis and Staphylococcus aureus, but shows no activity against gram-negative bacteria or yeasts. Notably, E. faecalis showed greater sensitivity to the enzyme than S. aureus at all tested concentrations.
Antioxidant capacity was evaluated via the DPPH radical scavenging assay. The enzyme showed a dose-dependent response, achieving maximum effectiveness (74.88%) at 200 μg/ml, with activity decreasing proportionally at lower concentrations. Furthermore, antitumor assessments were conducted on the breast cancer cell line (MCF-7) and a normal human dermal fibroblast line (HdFn). The findings revealed that the concentration of 400 μg/ml resulted in the lowest cell viability for both lines (40.5% for MCF-7 and 75.7% for HdFn). The calculated IC50 values were 118.6 μg/ml for the cancerous MCF-7 cells and 781.7 μg/ml for the normal HdFn cells. These results indicate that the protease enzyme from I. tamaricis possesses significant antioxidant properties and selective antitumor activity with low toxicity to normal cells, highlighting its potential for pharmaceutical applications.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Cheung A, Kwo P. Viral hepatitis other than A, B, and C: evaluation and management. Clinics in liver disease. 2020;24(3):405-19.
https://doi.org/10.1016/j.cld.2020.04.008
2. Mitchell AE, Colvin HM. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. 2010.
3. Naqid IA, Mahmood AJ, Mosa AA, Ahmed ZS, Abdullah AS, Abdulkareem DS, et al. Hepatitis B and C virus infection among couples undergoing premarital screening in Iraqi Kurdistan. IJID regions. 2025;14:100492.
https://doi.org/10.1016/j.ijregi.2024.100492
4. Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, et al. Hepatitis B virus infection: overview. Hepatitis B Virus Infection: Molecular Virology to Antiviral Drugs. 2020:1-16. https://doi.org/10.1007/978-981-13-9151-4_1
5. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nature microbiology. 2020;5(6):796-812.
6. Rybicka M, Bielawski KP. Recent advances in understanding, diagnosing, and treating hepatitis B virus infection. Microorganisms. 2020;8(9):1416. https://www.mdpi.com/2076-2607/8/9/1416#
7. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World journal of gastroenterology. 2016;22(34):7824. https://doi.org/10.3748/wjg.v22.i34.7824
8. Ibrahim OF. The Adverse consequence of covid-19 causing liver and kidney dysfunctions. Tikrit Journal of Pure Science. 2022;27(5):1-6. https://doi.org/10.25130/tjps.v27i5.12
9. Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver International. 2009;29:9-14. http://dx.doi.org/10.1111/j.1478-3231.2008.0 1926.x
10. Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus–related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73(2):661-73.
http://dx.doi.org/10.1002/hep.31289
11. Lee J, Conniff J, Kraus C, Schrager S. A Brief Clinical Update on Hepatitis C--The Essentials. WMJ: official publication of the State Medical Society of Wisconsin. 2015;114(6):263-9; quiz 70.
12. Sagnelli E, Coppola N, Marrocco C, Coviello G, Rossi G, Battaglia M, et al. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. Journal of biological regulators and homeostatic agents. 2003;17(2):207-10.
13. AL-Bashar SH, Badawy AS, Mohammed BA-R. Real time-PCR, ELISA, as an identification methods for Detection respiratory syncytial virus in children. Tik J of Pure Sci. 2018;22(2):33-42.
14. Akhtar N, Bilal M, Rizwan M, Khan MA, Khan A. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan. Asian Pacific Journal of Cancer Prevention. 2015;16(3):1037-40.
http://dx.doi.org/10.7314/apjcp.2015.16.3.1037
15. Tariq M, Shoukat AB, Akbar S, Hameed S, Naqvi MZ, Azher A, et al. Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. SAGE Open Medicine. 2022;10:20503121221105957. https://doi.org/10.1177/20503121221105957
16. Bibi S, Dars S, Ashfaq S, Qazi RA, Akhund S. Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh. Pakistan Journal of Medical Sciences. 2013;29(2):505. https://doi.org/10.12669/pjms.292.3211
17. Shafiq MI, Gauhar A, Akram M, Elahi S. Thyroid Peroxidase Antibodies in Non‐Interferon Treated Hepatitis C Patients in Pakistan. BioMed Research International. 2015;2015(1):172981. https://doi.org/10.1155/2015/172981
18. Asad M, Ahmed F, Zafar H, Farman S. Frequency and determinants of Hepatitis B and C virus in general population of Farash Town, Islamabad. Pakistan journal of medical sciences. 2015;31(6):1394. https://doi.org/10.12669/pjms.316.7047
19. Awan ZUR, Shah AH, Khan S, Rahman SU, Rahman HMU. Molecular prevalence of Hepatitis B virus infection in Khyber Pakhtunkhwa, Pakistan. Int J Med Med Sci. 2012;4:123-7.
https://doi.org/10.5897/IJMMS12.095
20. Ahmed F, Irving W, Anwar M, Myles P, Neal K. Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan: most infections remain unexplained. A cross-sectional study. Epidemiology & Infection. 2012;140(4):716-23. https://doi.org/10.1017/S0950268811001087
21. Toukan A. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. The Middle East Regional Study Group. Vaccine. 1990;8 Suppl:S117-21; discussion S34-8. https://doi.org/10.1016/0264-410x(90)90229-f
22. Ahmad GM, Al-Hayani NN, Abdulla AM. Evaluation of liver function tests in Hepatitis A, B and C in children in Ramadi city. Evaluation. 2024;18(01):40-8. http://dx.doi.org/10.37652/juaps.2023.143520.1139
23. Hussein NR, Haj SM, Almizori LA, Taha AA. The prevalence of hepatitis B and C viruses among blood donors attending blood bank in Duhok, Kurdistan region, Iraq. Int J Infect. 2017;4(1):e39008.
https://doi.org/10.17795/iji-39008
24. Al-Juboury AW, Salih H, Al-Assadi MK, Ali AM. Seroprevalence of Hepatitis B and C among blood donors in Babylon Governorate-Iraq. Med J Babylon. 2010;7(1-2):121-9.
25. Abass YA, Al-Husseiny KR, Kareem AA. Epidemiology of Hepatitis HBV and HCV at Thi-Qar Province –Iraq. Al-Qadisiyah Medical Journal. 2008;4(5):154-65.
https://doi.org/10.28922/qmj.2008.4.5.154-165
26. Hassan MS, Mourad YH, Elghobary MA. Diabetogenic effect of hepatitis C virus and insulin resistance among chronic hepatitis C patients. The Egyptian Journal of Internal Medicine. 2016;28:149-54.
27. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol. 2008;6(8):864-76. https://doi.org/10.1016/j.cgh.2008.03.024
28. Salman A, Abbas I, Hwaid A. Prevalence of occult hepatitis B infection in Diyala province, Iraq. Journal of Ideas in Health. 2022;5:685-92. https://doi.org/10.47108/jidhealth.Vol5.Iss2.215
29. Tarky AM, Akram WA, Al-Naaimi AS, Omer AR. Epidemiology of viral hepatitis B and C in Iraq: a national survey 2005-2006. Zanco Journal of Medical Sciences (Zanco J Med Sci). 2013;17(1):370_80. https://doi.org/10.15218/zjms.2013.0017
30. Al-Khafaji Z. A Study of Hepatitis B Vrius Precore Mutant among Iraqi Chronic Hepatitis B Pateints Treated with Interferon Alpha 2006.
31. Radii IJ, Saud AM. Comparative assessment between serological and molecular diagnosis for patients groups with hepatitis b virus. Int J Curr Microbiol App Sci. 2017;6(3):742-8.
http://dx.doi.org/10.20546/ijcmas.2017.603.086
32. Aljumaili Z. Hepatitis C Virus Prevalence among Patients with Beta Thalassemia Major in Iraq: A Systematic Review.: HCV in Thalassemia Major. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES. 2021;4(3):6-16.
https://orcid.org/0000-0003-1723-1967
33. Kandi V, Vinjamuri SR, Tanikella BP. Hepatitis C Viral Infection Among Beta-Thalassemia Patients: A Study From the Centre for Excellence in Thalassemia and Other Blood Disorders. Cureus. 2021;13(7):e16207.
34. Al-Hamadany AYM. Estimation of serum immunoglobulin E level in asthma and its correlation with Epstein Barr Virus (EBV) infection. Tikrit Journal of Pure Science. 2018;23(9):12-5. http://dx.doi.org/10.25130/tjps.23.2018.143
35. Rafal A, Arkan Hashim I, Batool Ali G. Prevalence of HBV, HCV, HIV, and Thalassemia among People Attending Premarital Screening Centers in Diyala, Governorate, 2015-2018. Journal of Science in Medicine and Life. 2024;2(2):96-106.
36. Amin S, Jalal S, Ali K, Rasool L, Osman T, Ali O, et al. Molecular characterization and disease-related morbidities of β-thalassemia patients from the northeastern part of Iraq. International Journal of General Medicine. 2020:1453-67.
https://doi.org/10.2147/IJGM.S277947
37. Di Bisceglie AM, King WC, Lisker‐Melman M, Khalili M, Belle SH, Feld JJ, et al. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Journal of viral hepatitis. 2019;26(7):856-65. https://doi.org/10.1111/jvh.13104
38. Tawfiq BA, RASHEED BN, Sulaiman SA. Prevalence of Hepatitis B and C Viruses in Alfa-Thalassemia Major and Beta-Thalassemia Major and Intermedia in Duhok City, Iraq. Ain Shams Medical Journal. 2024;75(3):673-81.
https://doi.org/10.21608/asmj.2024.308560.1291
39. Ryerson AB. Vital signs: newly reported acute and chronic hepatitis C cases―United States, 2009–2018. MMWR Morbidity and mortality weekly report. 2020;69.
http://dx.doi.org/10.15585/mmwr.mm6914a2
40. Yaqoob AM, Manhal FS. FREQUENCY OF HEPATITIS C VIRUS INFECTION AMONG BETA-THALASSEMIA PATIENTS IN BAGHDAD CITY, IRAQ. Journal Port Science Research. 2022;5(1):21-8.